Your browser doesn't support javascript.
loading
CDR1as promotes arrhythmias in myocardial infarction via targeting the NAMPT-NAD+ pathway.
Liu, Yunqi; Wang, Jiapan; Zhao, Xiuye; Li, Wen; Liu, Yaohua; Li, Xingda; Zhao, Dan; Yu, Jie; Ji, Hongyu; Shao, Bing; Li, Zhendong; Wang, Jia; Yang, Yilian; Hao, Yan; Wu, Yuting; Yuan, Ye; Du, Zhimin.
Afiliação
  • Liu Y; Institute of Clinical Pharmacology, The Second Affiliated Hospital of Harbin Medical University (University Key Laboratory of Drug Research, Heilongjiang Province), Harbin 150086, China; Department of Clinical Pharmacology, College of Pharmacy, Harbin Medical University, Harbin 150081, China.
  • Wang J; Institute of Clinical Pharmacology, The Second Affiliated Hospital of Harbin Medical University (University Key Laboratory of Drug Research, Heilongjiang Province), Harbin 150086, China; Department of Clinical Pharmacology, College of Pharmacy, Harbin Medical University, Harbin 150081, China.
  • Zhao X; Institute of Clinical Pharmacology, The Second Affiliated Hospital of Harbin Medical University (University Key Laboratory of Drug Research, Heilongjiang Province), Harbin 150086, China; Department of Clinical Pharmacology, College of Pharmacy, Harbin Medical University, Harbin 150081, China.
  • Li W; Institute of Clinical Pharmacology, The Second Affiliated Hospital of Harbin Medical University (University Key Laboratory of Drug Research, Heilongjiang Province), Harbin 150086, China; Department of Clinical Pharmacology, College of Pharmacy, Harbin Medical University, Harbin 150081, China.
  • Liu Y; Institute of Clinical Pharmacology, The Second Affiliated Hospital of Harbin Medical University (University Key Laboratory of Drug Research, Heilongjiang Province), Harbin 150086, China; Department of Clinical Pharmacology, College of Pharmacy, Harbin Medical University, Harbin 150081, China.
  • Li X; Institute of Clinical Pharmacology, The Second Affiliated Hospital of Harbin Medical University (University Key Laboratory of Drug Research, Heilongjiang Province), Harbin 150086, China; Department of Clinical Pharmacology, College of Pharmacy, Harbin Medical University, Harbin 150081, China.
  • Zhao D; Institute of Clinical Pharmacology, The Second Affiliated Hospital of Harbin Medical University (University Key Laboratory of Drug Research, Heilongjiang Province), Harbin 150086, China; Department of Clinical Pharmacology, College of Pharmacy, Harbin Medical University, Harbin 150081, China.
  • Yu J; Institute of Clinical Pharmacology, The Second Affiliated Hospital of Harbin Medical University (University Key Laboratory of Drug Research, Heilongjiang Province), Harbin 150086, China; Department of Clinical Pharmacology, College of Pharmacy, Harbin Medical University, Harbin 150081, China.
  • Ji H; Institute of Clinical Pharmacology, The Second Affiliated Hospital of Harbin Medical University (University Key Laboratory of Drug Research, Heilongjiang Province), Harbin 150086, China; Department of Clinical Pharmacology, College of Pharmacy, Harbin Medical University, Harbin 150081, China.
  • Shao B; Institute of Clinical Pharmacology, The Second Affiliated Hospital of Harbin Medical University (University Key Laboratory of Drug Research, Heilongjiang Province), Harbin 150086, China; Department of Clinical Pharmacology, College of Pharmacy, Harbin Medical University, Harbin 150081, China.
  • Li Z; Institute of Clinical Pharmacology, The Second Affiliated Hospital of Harbin Medical University (University Key Laboratory of Drug Research, Heilongjiang Province), Harbin 150086, China; Department of Clinical Pharmacology, College of Pharmacy, Harbin Medical University, Harbin 150081, China.
  • Wang J; Institute of Clinical Pharmacology, The Second Affiliated Hospital of Harbin Medical University (University Key Laboratory of Drug Research, Heilongjiang Province), Harbin 150086, China; Department of Clinical Pharmacology, College of Pharmacy, Harbin Medical University, Harbin 150081, China.
  • Yang Y; Institute of Clinical Pharmacology, The Second Affiliated Hospital of Harbin Medical University (University Key Laboratory of Drug Research, Heilongjiang Province), Harbin 150086, China; Department of Clinical Pharmacology, College of Pharmacy, Harbin Medical University, Harbin 150081, China.
  • Hao Y; Institute of Clinical Pharmacology, The Second Affiliated Hospital of Harbin Medical University (University Key Laboratory of Drug Research, Heilongjiang Province), Harbin 150086, China; Department of Clinical Pharmacology, College of Pharmacy, Harbin Medical University, Harbin 150081, China.
  • Wu Y; Institute of Clinical Pharmacology, The Second Affiliated Hospital of Harbin Medical University (University Key Laboratory of Drug Research, Heilongjiang Province), Harbin 150086, China; Department of Clinical Pharmacology, College of Pharmacy, Harbin Medical University, Harbin 150081, China.
  • Yuan Y; Institute of Clinical Pharmacology, The Second Affiliated Hospital of Harbin Medical University (University Key Laboratory of Drug Research, Heilongjiang Province), Harbin 150086, China; Department of Clinical Pharmacology, College of Pharmacy, Harbin Medical University, Harbin 150081, China; Nation
  • Du Z; Institute of Clinical Pharmacology, The Second Affiliated Hospital of Harbin Medical University (University Key Laboratory of Drug Research, Heilongjiang Province), Harbin 150086, China; Department of Clinical Pharmacology, College of Pharmacy, Harbin Medical University, Harbin 150081, China; Nation
Biomed Pharmacother ; 165: 115267, 2023 Sep.
Article em En | MEDLINE | ID: mdl-37542851
ABSTRACT
Cardiac ventricular arrhythmia triggered by acute myocardial infarction (AMI) is a major cause of sudden cardiac death. We have reported previously that an increased serum level of circular RNA CDR1as is a potential biomarker of AMI. However, the possible role of CDR1as in post-infarct arrhythmia remains unclear. This study in MI mice investigated the effects and underlying mechanism of CDR1as in ventricular arrhythmias associated with MI. We showed that knockdown of CDR1as abbreviated the duration of the abnormally prolonged QRS complex and QTc intervals and decreased susceptibility to ventricular arrhythmias. Optical mapping demonstrated knockdown of CDR1as also reduced post-infarct arrhythmia by increasing the conduction velocity and decreasing dispersion of repolarization. Mechanistically, CDR1as led to the depletion of NAD+ and caused mitochondrial dysfunction by directly targeting the NAMPT protein and repressing its expression. Moreover, CDR1as aggravated dysregulation of the NaV1.5 and Kir6.2 channels in cardiomyocytes, a change which was alleviated by the replenishment of NAD+. These findings suggest that anti-CDR1as is a potential therapeutic approach for ischemic arrhythmias.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infarto do Miocárdio / NAD Tipo de estudo: Etiology_studies Limite: Animals Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infarto do Miocárdio / NAD Tipo de estudo: Etiology_studies Limite: Animals Idioma: En Ano de publicação: 2023 Tipo de documento: Article